Altered Kinetics and Benzodiazepine Sensitivity of a GABAA Receptor Subunit Mutation [␥2(R43Q)] Found in Human Epilepsy

Total Page:16

File Type:pdf, Size:1020Kb

Altered Kinetics and Benzodiazepine Sensitivity of a GABAA Receptor Subunit Mutation [␥2(R43Q)] Found in Human Epilepsy Altered kinetics and benzodiazepine sensitivity of a GABAA receptor subunit mutation [␥2(R43Q)] found in human epilepsy David N. Bowser*†, David A. Wagner†‡, Cynthia Czajkowski‡, Brett A. Cromer§, Michael W. Parker§, Robyn H. Wallace¶, Louise A. Harkin¶, John C. Mulley¶, Carla Mariniʈ, Samuel F. Berkovicʈ, David A. Williams*, Mathew V. Jones‡, and Steven Petrou*,** *Department of Physiology, University of Melbourne, Victoria 3010, Australia; ‡Department of Physiology, University of Wisconsin, Madison, WI 53706; §Biota Structural Biology Laboratory, St. Vincent’s Institute for Medical Research, Fitzroy, Victoria 3065, Australia; ¶Centre for Medical Genetics, Department of Cytogenetics and Molecular Genetics, Women’s and Children’s Hospital, Adelaide, SA 5006, Australia; and ʈEpilepsy Research Institute and Department of Medicine (Neurology), University of Melbourne, and Austin and Repatriation Medical Centre, Heidelberg, Victoria 3081, Australia Edited by Bert Sakmann, Max Planck Institute for Medical Research, Heidelberg, Germany, and approved September 3, 2002 (received for review May 28, 2002) ␥ The -aminobutyric acid type A (GABAA) receptor mediates fast GABAA receptor is a heterooligomeric complex of five subunits. inhibitory synaptic transmission in the CNS. Dysfunction of the Each subunit has a large, N-terminal extracellular domain, four GABAA receptor would be expected to cause neuronal hyperexcit- transmembrane domains, and a small, extracellular C-terminal ability, a phenomenon linked with epileptogenesis. We have tail. Multiple subunits have been cloned and divided into families investigated the functional consequences of an arginine-to- based on their sequence homology. The subunits also are ␥ glutamine mutation at position 43 within the GABAA 2-subunit differentially expressed in various brain regions and confer found in a family with childhood absence epilepsy and febrile distinct pharmacology to the expressed GABAA receptor (15, seizures. Rapid-application experiments performed on receptors 16). Most native receptors contain ␣-, ␤-, and ␥-subunits, with expressed in HEK-293 cells demonstrated that the mutation slows ␣ ␤ ␥ 1 2 2 being the most common combination (17). The receptor GABAA receptor deactivation and increases the rate of desensiti- has two GABA-binding sites formed by the extracellular do- zation, resulting in an accumulation of desensitized receptors mains at the interface of ␣␤-subunits. The receptor also is during repeated, short applications. In Xenopus laevis oocytes, modulated allosterically by benzodiazepines, believed to bind at two-electrode voltage-clamp analysis of steady-state currents ob- the interface of ␣␥-subunits. Binding of benzodiazepines poten- ␣ ␤ ␥ ␣ ␤ ␥ tained from 1 2 2 or 1 2 2(R43Q) receptors did not reveal any tiates GABA-activated ClϪ currents but, alone, is unable to differences in GABA sensitivity. However, differences in the ben- activate the receptor. The exact mechanism of receptor modu- zodiazepine pharmacology of mutant receptors were apparent. lation by benzodiazepines remains unclear. Mutant receptors expressed in oocytes displayed reduced sensi- Mutations in GABA receptor subunit genes recently have tivity to diazepam and flunitrazepam but not the imidazopyridine A been described in human epilepsy (18–20). Two families with the zolpidem. These results provide evidence of impaired GABA A GEFSϩ phenotype had different mutations in the ␥ -subunit receptor function that could decrease the efficacy of transmission 2 gene, severely reducing or abolishing ClϪ currents in response to at inhibitory synapses, possibly generating a hyperexcitable neu- GABA in Xenopus laevis oocytes. A French family (20) had a ronal state in thalamocortical networks of epileptic patients pos- sessing the mutant subunit. K289M mutation that resulted in an amino acid change in the extracellular loop between the second and third transmembrane ͉ ͉ domains. We described an Australian family with a nonsense rapid agonist application two-electrode voltage clamp Xenopus oocytes ␥ mutation that caused truncation of the 2-subunit at position 351 between the third and forth transmembrane domains (19). pilepsy, one of the most common neurological disorders, is Heteromeric GABA receptor complexes containing GFP- Echaracterized by episodic seizures that are caused by parox- ␥ tagged truncated 2-subunits were found to be trapped within ysmal, synchronized discharges of hyperexcitable neuronal pop- the endoplasmic reticulum, thereby inhibiting expression at the ulations. Many human epileptic syndromes have a genetic com- cell membrane. Different phenotypes of simple febrile seizures, ponent, and the molecular basis of a few inherited epilepsies is childhood absence epilepsy and GEFSϩ, were observed in a now known (1). Most genes implicated in epilepsy to date code large Australian family with a missense mutation in the extra- for ion channel subunits, both ligand-gated and voltage-gated cellular domain of the ␥ -subunit (18). The mutation (R43Q) (2). For example, mutations within the ␣- and ␤-subunits of the 2 resulted in the replacement of a highly conserved arginine, found voltage-gated sodium channel family have been found in families in most ligand-gated receptor subunits, for a glutamine at with generalized epilepsy with febrile seizures plus (GEFSϩ; position 43. Although expression of this mutant subunit in refs. 3 and 4). Mutations within the voltage-gated potassium Ϫ channel subunits KCNQ2 and KCNQ3 cause the benign familial X. laevis oocytes did not alter GABA-induced Cl currents, lack neonatal convulsions phenotype (5–9), whereas mutations in the of potentiation of such currents with low benzodiazepine con- acetylcholine ligand-gated receptor family are responsible for centrations was observed. familial nocturnal frontal lobe epilepsy (10–14). In vitro inves- tigations with the oocyte expression system and two-electrode This paper was submitted directly (Track II) to the PNAS office. voltage-clamp assay generally suggest that these mutations Abbreviations: GABAA, ␥-aminobutyric acid type A (receptor); GEFSϩ, generalized epilepsy would result in neuronal hyperexcitability. with febrile seizures plus; HEK, human embryonic kidney. ␥ The -aminobutyric acid type A (GABAA) receptor is the † Ϫ D.N.B. and D.A.W. contributed equally to this work. predominant ligand-gated Cl ion channel conferring fast in- **To whom correspondence should be addressed at: Laboratory of Biophysics and Molec- hibitory synaptic transmission in the CNS and, therefore, is a ular Physiology, Department of Physiology, University of Melbourne, Victoria 3010, prime candidate for involvement in epileptogenesis. The Australia. E-mail: [email protected]. 15170–15175 ͉ PNAS ͉ November 12, 2002 ͉ vol. 99 ͉ no. 23 www.pnas.org͞cgi͞doi͞10.1073͞pnas.212320199 Downloaded by guest on September 29, 2021 Impaired sensitivity to benzodiazepines may explain some Expression in HEK-293 Cells and Outside-Out Patch-Clamp Assay. aspects of the epilepsy phenotypes observed. Here, we postulate HEK-293 cells were cultured in minimum essential medium with ␥ that the 2(R43Q) mutation may have additional and significant Earle’s salts (Life Technologies) containing 10% FBS (Sigma) in pathophysiological effects. This is due, in part, to the observation a37°C incubator under a 5% CO2 atmosphere. When the cells that R43 is so highly conserved amongst other ligand-gated reached 60–90% confluence in 60-mm culture dishes, they were ␮ ␣ ␤ ␥ channels that do not interact with benzodiazepines that it may transfected with 1 g each of 1, 2, and 2 (WT or R43Q) play a more fundamental role in receptor function. We now have cDNAs subcloned into the pcDNA3.1(ϩ) vector and 200 ng of examined both GABA sensitivity and responses to benzodiaz- a vector containing the T cell membrane antigen CD8 cDNA epines by using two-electrode voltage-clamp recordings of (gift from Robert Coronado, Univ. of Wisconsin, Madison, WI) Xenopus oocytes heterologously expressing WT and mutation by using the Lipofectamine 2000 reagent (GIBCO) according to GABA receptors. The oocyte system, however, has relatively the supplied protocol. Twenty to 28 h posttransfection, the cells slow temporal resolution, whereas during synaptic transmission, were replated on 12-mm sterile glass coverslips, transferred to a receptors are activated by pulses of neurotransmitter that reach 30°C incubator, and recorded at 24–96 h postreplating. Trans- millimolar concentrations and decay within a millisecond (21). fected cells were recognized by incubation with anti-CD8 anti- To obtain sufficient temporal resolution, we used rapid-solution body beads (Dynal, Oslo). switches on outside-out patches from human embryonic kidney Recordings from outside-out patches excised from HEK cells (HEK-293) cells to approximate the conditions at synapses. We were made by using borosilicate glass pipettes filled with 140 mM ␥ ͞ ͞ ͞ found that the 2(R43Q) mutation slows receptor deactivation KCl 10 mM EGTA 2mMMgATP20 mM phosphocre- and increases fast desensitization. These kinetic differences atine͞10 mM Hepes, pH 7.3. Patches were voltage-clamped at could lead to reduced inhibition during periods of high activity Ϫ60 mV and placed in the stream of a multibarreled flowpipe and, thus, contribute to the epileptic phenotypes. array (Vitro Dynamics, Rockaway, NY) mounted on a piezo- electric bimorph (Vernitron, Bedford, OH). A computer- Materials and Methods controlled constant current source drove the bimorph to move Construction of
Recommended publications
  • Zolpidem Tartrate) Orally Disintegrating Tablets CIV
    NDA 21-412 FDA Approved Labeling Text dated April 25, 2007 Page 1 TOVALT™ ODT (zolpidem tartrate) Orally Disintegrating Tablets CIV Rx Only LB Rev. 04/07 DESCRIPTION TOVALT™ ODT (zolpidem tartrate) Orally Disintegrating Tablets is a non- benzodiazepine hypnotic of the imidazopyridine class and is available in 5 mg and 10 mg tablet strengths for oral administration. Chemically, zolpidem is N,N,6-trimethyl-2-p-tolyl-imidazo[1,2-a]pyridine-3-acetamide L-( + )-tartrate (2:1). It has the following structure: Zolpidem tartrate is a white to off-white crystalline powder that is sparingly soluble in water, alcohol, and propylene glycol. It has a molecular weight of 764.88. Each TOVALT ODT includes the following inactive ingredients: Acesulfame Potassium, Glyceryl Monostearate, Hypromellose, Stearoyl Macrogolglycerides Polyacrylate Dispersion (30%), Talc, Mannitol, Microcrystalline Cellulose, Low Substituted Hydroxypropyl Cellulose, Crospovidone, Sodium Stearyl Fumarate, Silicon Dioxide, Monoammonium Glycyrrhizinate, Natural Intense Peppermint Flavour, FD&C Blue #2 (for 10mg only). CLINICAL PHARMACOLOGY Pharmacodynamics Subunit modulation of the GABAA receptor chloride channel macromolecular complex is hypothesized to be responsible for sedative, anticonvulsant, anxiolytic, and myorelaxant NDA 21-412 FDA Approved Labeling Text dated April 25, 2007 Page 2 drug properties. The major modulatory site of the GABAA receptor complex is located on its alpha (α) subunit and is referred to as the benzodiazepine (BZ) or omega (ω) receptor. At least three subtypes of the (ω) receptor have been identified. While zolpidem is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with a GABA-BZ receptor complex and shares some of the pharmacological properties of the benzodiazepines.
    [Show full text]
  • Original Research Article
    Original Research Article IN SILICO LIGAND-BASED 2D PHARMACOPHORE GENERATION FOR H+/K+ ATPASE INHIBITORS ABSTRACT Objectives: At the beginning of the 20th century, Peptic Ulcer became the most prevalent disease as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) proved ineffective. Researches proved proton pump inhibitors as most successful drugs for the treatment of peptic ulcer. Hence, a ligand based pharmacophore was generated on LigandScout based on fifteen selected H+/K+ ATPase inhibitors. Methods: A pharmacophore model with three Hydrogen bond acceptors, one Hydrogen bond donor and one Hydrophobic Domain was developed. The distance between these features was estimated on Visual Molecular Dynamics (VMD) software. Results: The range between HBA-HBD was found to be 1.89-2.96A. The range between HBD-HP was 4.00-5.46A and range between HP-HBA was 1.89-2.96A. Conclusion: This research study will thus help in designing new and effective drugs for the treatment of peptic ulcer disease. Key words: Peptic Ulcer, NSAIDs, ligand, pharmacophore, Visual Molecular Dynamics INTRODUCTION Gastric H+/K+ ATPase pump is located in the parietal cells [1] and plays a crucial role in the formation of ulcers in the stomach. H pylori transmission occurs in 50% of the people worldwide [2]. A peptic ulcer is caused by Helicobacter pylori (H. pylori) infection in the gastric mucosal lining. This bacterium causes inflammation in the lining of the stomach. In response to this, gastrin hormone stimulates the gastric acid production. High levels of gastrin cause the enhance release of acid through H+/K+ ATPase pump and lead to the formation of the ulcer.
    [Show full text]
  • Herbal Remedies and Their Possible Effect on the Gabaergic System and Sleep
    nutrients Review Herbal Remedies and Their Possible Effect on the GABAergic System and Sleep Oliviero Bruni 1,* , Luigi Ferini-Strambi 2,3, Elena Giacomoni 4 and Paolo Pellegrino 4 1 Department of Developmental and Social Psychology, Sapienza University, 00185 Rome, Italy 2 Department of Neurology, Ospedale San Raffaele Turro, 20127 Milan, Italy; [email protected] 3 Sleep Disorders Center, Vita-Salute San Raffaele University, 20132 Milan, Italy 4 Department of Medical Affairs, Sanofi Consumer HealthCare, 20158 Milan, Italy; Elena.Giacomoni@sanofi.com (E.G.); Paolo.Pellegrino@sanofi.com (P.P.) * Correspondence: [email protected]; Tel.: +39-33-5607-8964; Fax: +39-06-3377-5941 Abstract: Sleep is an essential component of physical and emotional well-being, and lack, or dis- ruption, of sleep due to insomnia is a highly prevalent problem. The interest in complementary and alternative medicines for treating or preventing insomnia has increased recently. Centuries-old herbal treatments, popular for their safety and effectiveness, include valerian, passionflower, lemon balm, lavender, and Californian poppy. These herbal medicines have been shown to reduce sleep latency and increase subjective and objective measures of sleep quality. Research into their molecular components revealed that their sedative and sleep-promoting properties rely on interactions with various neurotransmitter systems in the brain. Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter that plays a major role in controlling different vigilance states. GABA receptors are the targets of many pharmacological treatments for insomnia, such as benzodiazepines. Here, we perform a systematic analysis of studies assessing the mechanisms of action of various herbal medicines on different subtypes of GABA receptors in the context of sleep control.
    [Show full text]
  • Drug Points BMJ: First Published As 10.1136/Bmj.318.7192.1179 on 1 May 1999
    Papers Drug points BMJ: first published as 10.1136/bmj.318.7192.1179 on 1 May 1999. Downloaded from Hepatotoxicity associated with zolpidem respectively. Retrograde endoscopic cholangiography had treatment shown no abnormality. David Karsenti, Pascal Blanc, Yannick Bacq, Etienne-Henry Metman, Six months later, in April 1997, she had had another Service d’Hépato-Gastroentérologie, Centre Hospitalier Universitaire episode of abdominal pain. Eleven days later alanine Trousseau, and Service de Pharmacologie Clinique, Centre aminotransferase and ã-glutamyl transpeptidase activities Hospitalier Universitaire Bretonneau, F-37044 Tours Cedex, France had been 50 IU/l and 89 IU/l respectively. Zolpidem is a hypnotic drug of the imidazopyridine In June 1997 ultrasound examination of the biliary group. Another imidazopyridine, alpidem, has been with- tract gave normal results. On questioning she remem- 12 drawn from the market because of its hepatotoxicity. bered that zolpidem had been reintroduced because her Hepatoxicity has been suspected in association with zolpi- insomnia had recurred (she had taken 20 mg two days dem, but it has not been clearly established because of before the last acute episode). Viral hepatitis and concur- 34 concomitant drug treatment. We report a case of acute rent infections with Epstein-Barr virus and cytomegalovi- hepatitis mimicking biliary lithiasis after treatment with rus were excluded. No antibodies against smooth muscle, zolpidem alone at a therapeutic dose, with reappearance liver and kidney microsomes, or liver cytosol or mitochon- of the hepatoxicity after the drug was reintroduced. dria were detected in serum. Five months later the results A 53 year old woman was admitted in June 1997 for of liver function tests remained within normal limits and investigation of recurrent abdominal pain.
    [Show full text]
  • HS 172 R5/13 Briefly Review the Objectives, Content and Activities of This Session
    HS 172 R5/13 Briefly review the objectives, content and activities of this session. Upon successfully completing this session the participant will be able to: • Explain a brief history of the CNS Depressant category of drugs. • Identify common drug names and terms associated with this category. • Identify common methods of administration for this category. • Describe the symptoms, observable signs and other effects associated with this category. CONTENT SEGMENTS LEARNING ACTIVITIES A. Overview of the Category Instructor-Led Presentations B. Possible Effects Instructor Led Demonstrations C. OtdDtifEfftOnset and Duration of Effects RdiAiReading Assignmen ts D. Overdose Signs and Symptoms Video Presentations E. Expected Results of the Evaluation Slide Presentations F. Classification Exemplar HS 172 R5/13 9-2 • Explain the typical time parameters, i.e. onset and duration of effects, associated with this category. • List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this category of drugs. • Correctly answer the “topics for study” questions at the end of this session. HS 172 R5/13 9-3 A. Overview of the Category CNS Depressants Central Nervous System Depressants slow down the operations of the brain. Point out that other common names for CNS Depressants are “downers” and “sedative-hypnotics.” • Depressants first affect those arareaseas of the brain that control a person’ s conscious, voluntary actions. • Judgment, inhibitions and reaction time are some of the things that CNS Depressants affect first. • As the dose is increased, depressants begin to affect the parts of the brain that control the body’s automatic processes, heartbeat, respiration, etc.
    [Show full text]
  • Pharmacological Aspects
    Pharmacological aspects Psychopharmacology of anxiety disorders Giovanni B. Cassano, MD; Nicolò Baldini Rossi, MD; Stefano Pini, MD A nxiety disorders are the most common and among the most disabling of mental disorders in adults and adolescents.1 Although many are highly circum- scribed fears of mild-to-moderate severity, it has been estimated by the Epidemiological Catchment Area (ECA) study2 that approximately one quarter of people will experience severe symptoms, disability, and handicap as a consequence of anxiety disorders at some time dur- ing their lifetime.These disorders are associated with sig- nificant morbidity3 and increased mortality, probably as a consequence of increased suicide rates among suffer- Exposure of the general population to a 1:4 lifetime risk of ers.The direct and indirect costs to the health service and disabling anxiety has inspired generations of fundamental economy are considerable.Although persons who suffer and clinical psychopharmacologists, from the era of the from anxiety disorders are high consumers of all types of earliest benzodiazepines (BZ) to that of the selective sero- health services, only a minority receive specific help.4 tonin reuptake inhibitors (SSRIs) and related compounds, The spectrum of anxiety disorders includes generalized eg, the serotonin and norepinephrine reuptake inhibitors anxiety disorder (GAD), panic disorder (PD) and ago- (SNRIs). This comprehensive practical review summarizes raphobia, obsessive-compulsive disorder (OCD), phobic current therapeutic research across the spectrum of indi- disorder (including social phobia), and posttraumatic vidual disorders: generalized anxiety disorder (GAD), panic stress disorder (PTSD). With the discovery of new psy- disorder (PD) and agoraphobia (social anxiety disorder), chotropic medications, specific diagnosis within this spec- compulsive disorder (OCD), phobic disorder (including trum is essential because each of these disorders social phobia), and posttraumatic stress disorder (PTSD).
    [Show full text]
  • 25 Years of Proton Pump Inhibitors: a Comprehensive Review
    Gut and Liver, Vol. 11, No. 1, January 2017, pp. 27-37 Review 25 Years of Proton Pump Inhibitors: A Comprehensive Review Daniel S. Strand1, Daejin Kim2, and David A. Peura1 1Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA, USA, and 2Division of Gastroenterology, Daegu Fatima Hospital, Daegu, Korea Proton pump inhibitors (PPIs) were clinically introduced more the modern gastroenterologist. For most, this class of drugs rep- than 25 years ago and have since proven to be invaluable, resents the first choice for treatment of esophagitis, nonerosive safe, and effective agents for the management of a variety of reflux disease (NERD), peptic ulcer disease (PUD), prevention of acid-related disorders. Although all members in this class act nonsteroidal anti-inflammatory drugs (NSAID) associated ulcers, in a similar fashion, inhibiting active parietal cell acid secre- Zollinger-Ellison syndrome (ZES), and functional dyspepsia.4-6 tion, there are slight differences among PPIs relating to their In combination with antibiotics, PPIs are also an integral part of pharmacokinetic properties, metabolism, and Food and Drug eradication therapy for Helicobacter pylori.7 Administration (FDA)-approved clinical indications. Neverthe- Despite an excellent safety profile throughout their first two less, each is effective in managing gastroesophageal reflux decades of use, the nearly universal popularity of PPIs has disease and uncomplicated or complicated peptic ulcer dis- prompted several concerns about both their short- and long- ease. Despite their overall efficacy, PPIs do have some limita- term effects.8,9 This review will examine the pharmacokinetics tions related to their short plasma half-lives and requirement and pharmacodynamics of these drugs and provide an update for meal-associated dosing, which can lead to breakthrough on both the clinical use of and remaining challenges with PPIs.
    [Show full text]
  • Proton Pump Inhibitors in Veterinary Medicine
    American Journal of Animal and Veterinary Sciences Review Proton Pump Inhibitors in Veterinary Medicine 1Oguzhan Yavuz and 2Handan Hilal Arslan 1Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun, Turkey 2Department of Internal Medicine, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun, Turkey Article history Abstract: Inhibition of gastric acid secretion is necessary to treat many Received: 01-04-2017 gastrointestinal diseases. Proton Pump Inhibitors (PPIs) are very effective Revised: 02-06-2017 drugs, used for gastric acid inhibition and therapy of important erosive and Accepted: 23-06-2017 non-erosive gastrointestinal disorders in animals as well as humans. In this review, general properties of PPIs, their mode of action, pharmacokinetics, Corresponding Author: OguzhanYavuz efficacy, adverse effects, drug interactions and clinical and alternative uses Department of Pharmacology in veterinary medicine were evaluated. and Toxicology, Faculty of Veterinary Medicine, Keywords: Gastrointestinal Disorders, Proton Pump Inhibitors, Veterinary OndokuzMayis University, Medicine Samsun, Turkey Tel: 00903623121919/2830 Fax: 00903624576922 E-mail: [email protected] Introduction All clinically used PPIs contain a pyridyl methylsulfinyl benzimidazole group and differ only type Gastric acid is the secretion of parietal cells of of substituents on the pyridine and benzimidazole rings stomach and it is controlled by paracrine, endocrine and + + (Kosma et al ., 2016). Some important physicochemical neuronal systems. An important enzyme, H /K ATPase, properties of PPIs are shown in Table 1. is the main actor to pump hydrogen ions into the + + stomach lumen (H /K proton pump) (Shin and Sachs, Mode of Action 2008; Hori et al ., 2011; Garcia-Mazcorro et al ., 2012).
    [Show full text]
  • Advances in Chalcones with Anticancer Activities
    Send Orders for Reprints to [email protected] Recent Patents on Anti-Cancer Drug Discovery, 2015, 10, 97-115 97 Advances in Chalcones with Anticancer Activities Chandrabose Karthikeyana, Narayana S. H. Narayana Moorthya,b, Sakthivel Ramasamyc, Uma Vanamc, Elangovan Manivannand, Devarajan Karunagaranc and Piyush Trivedia,* aSchool of Pharmaceutical Sciences, Rajiv Gandhi Proudyogiki Vishwavidyalaya, Airport Bypass Road, Gandhi Nagar, Bhopal, MP, 462036, India; bDepartment of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 687, Rua de Campo Alegre, Porto, 4169-007, Portugal; cCancer Biology Laboratory, Department of Biotechnology, Bhupat & Jyoti Mehta School of Biosciences Building, Indian Institute of Technology Madras, Chennai-600036 (T.N.), India; dSchool of Pharmacy, Devi Ahilya Vishwavidyalaya, Indore 452 017, MP, India Received: January 7, 2014; Accepted: July 21, 2014; Revised: July 29, 2014 Chandrabose Karthikeyan Abstract: Chalcones are naturally occurring compounds exhibiting broad spectrum biological activities including anticancer activity through multiple mechanisms. Literature on anticancer chalcones highlights the employment of three pronged strate- gies, namely; structural manipulation of both aryl rings, replacement of aryl rings with heteroaryl scaffolds, molecular hy- bridization through conjugation with other pharmacologically interesting scaffolds for enhancement of anticancer properties. Methoxy substitutions on both the aryl rings (A and B) of the chalcones, depending upon their positions in the aryl rings ap- pear to influence anticancer and other activities. Similarly, heterocyclic rings either as ring A or B in chalcones, also influence the anticancer activity shown by this class of compounds. Hybrid chalcones formulated by chemically linking chalcones to other prominent anticancer scaffolds such as pyrrol[2,1-c][1,4]benzodiazepines, benzothiazoles, imidazolones have demon- strated synergistic or additive pharmacological activities.
    [Show full text]
  • Pharmacology Cito
    Pharmacology Cito 5 Read: it is important! Dear future physicians and pharmaceutists! The scientific and pedagogical staff of the Pharmacology department of the National University of Pharmacy (Kharkiv) presents a new textbook "Pharmacology – Cito!" to you. We want to change the myth that it is impossible to learn pharmacology quickly and qualitatively. The textbook "Pharmacology – Cito!" is published for those, who have decided to connect his or her profession with medicines, but think that a great amount of the information in pharmacology is hard to learn. Taking this fact into account we have decided to help those, who wish to master pharmacology in logical, fast - "Cito!"- version. Not be afraid of pharmacology! The 40-year experience of teaching pharmacology testifies that for the last 10-15 years a tendency of reducing the amount of classroom hours in pharmacology because of increasing the amount of the individual work is being observed. However, because of the lack of time and the constant increasing volume of information in pharmacology, everyone has not enough time to master it soundly and qualitatively. This textbook trains future pharmaceutists and physicians in the pharmacological logic, i.e. knowing the mechanisms of drug action one can understand their pharmacodynamics, naturally, on the basis of pharmacodynamics one can find logically the indications to their application and from their side effects the contraindications can be seen. The information about the peculiarities of medicines has been generalized and given as a pharmacological ―face‖ in tables. The volume of this textbook in pharmacology is sufficient for acquiring the confidence in the opportunity of the further improving of knowledge in this discipline, which is important for a physician and a pharmaceutist.
    [Show full text]
  • Anxiety Disorders, Insomnia, PTSD, OCD
    2/3/2020 Anxiety Disorders, Insomnia, PTSD, OCD Steven L. Dubovsky, M.D. 1 2/3/2020 Basic Benzodiazepine Structure R1 R2 N C R7 C R3 C=N R4 R2′ Benzodiazepine R1 R2 R3 R7 R2′ Alprazolam Fused triazolo ring -H -Cl -H Chlordiazepoxide - -NHCH3 -H -Cl -H Clonazepam -H =O -H NO2 -Cl Diazepam -CH3 =O -H -Cl -H 2 2/3/2020 GABA-Benzodiazepine Receptor Complex GABA BZD Cl- 3 2/3/2020 Benzodiazepine Action GABA Cl- + + BZD - Cl- Inverse agonist Flumazenil • Benzodiazepine receptor antagonist R1 R2 • Therapeutic uses: C N – Benzodiazepine overdose R3 C R7 N C – Reversal of conscious sedation R4 = – Reversal of hepatic encephalopathy symptoms R2′ – Facilitation of benzodiazepine withdrawal • Can provoke withdrawal and induce anxiety 4 2/3/2020 BZD Receptor Subtypes • Type 1: Limbic system, locus coeruleus – Anxiolytic • Type 2: Cortex, pyramidal cells – Muscle relaxation, anticonvulsant, CNS depression, sedation, psychomotor impairment • Type 3: Mitochondria, periphery – Dependence, withdrawal BZD Features • Potency – High potency: Midazolam (Versed), alprazolam (Xanax), triazolam (Halcion) – Low potency: Chlordiazepoxide (Librium), flurazepam (Dalmane) • Lipid solubility – High solubility: Alprazolam, diazepam (Valium) – Low solubility: Lorazepam (Ativan), chlordiazepoxide (Librium) • Elimination half-life – Long half-life: Diazepam, chlordiazepoxide – Short half-life: Alprazolam, midazolam 5 2/3/2020 Potency • High potency – Smaller dose to produce same effect – More receptor occupancy – More intense withdrawal • Low potency – Higher doses used
    [Show full text]
  • UCLA Previously Published Works
    UCLA UCLA Previously Published Works Title Novel Approaches to Inhibition of Gastric Acid Secretion Permalink https://escholarship.org/uc/item/6319s54m Journal Current Gastroenterology Reports, 12(6) ISSN 1534-312X Authors Sachs, George Shin, Jai Moo Hunt, Richard Publication Date 2010-12-01 DOI 10.1007/s11894-010-0149-5 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Curr Gastroenterol Rep (2010) 12:437–447 DOI 10.1007/s11894-010-0149-5 Novel Approaches to Inhibition of Gastric Acid Secretion George Sachs & Jai Moo Shin & Richard Hunt Published online: 6 October 2010 # The Author(s) 2010. This article is published with open access at Springerlink.com Abstract The gastric H,K-adenosine triphosphatase and the requirement for acid activation impair their efficacy (ATPase) is the primary target for treatment of acid- in acid suppression, particularly at night. All PPIs give related diseases. Proton pump inhibitors (PPIs) are weak excellent healing of peptic ulcer and produce good, but less bases composed of two moieties, a substituted pyridine than satisfactory, results in reflux esophagitis. PPIs combined with a primary pKa of about 4.0 that allows selective with antibiotics eradicate Helicobacter pylori, but success has accumulation in the secretory canaliculus of the parietal fallen to less than 80%. Longer dwell-time PPIs promise to cell, and a benzimidazole with a second pKa of about 1.0. improve acid suppression and hence clinical outcome. Protonation of this benzimidazole activates these prodrugs, Potassium-competitive acid blockers (P-CABs) are another converting them to sulfenic acids and/or sulfenamides that class of ATPase inhibitors, and at least one is in develop- react covalently with one or more cysteines accessible from ment.
    [Show full text]